E-resources
Peer reviewed
Open access
-
Smith-Jeffcoat, Sarah E; Biddle, Jessica E; Talbot, H Keipp; Morrissey, Kerry Grace; Stockwell, Melissa S; Maldonado, Yvonne; McLean, Huong Q; Ellingson, Katherine D; Bowman, Natalie M; Asturias, Edwin; Mellis, Alexandra M; Johnson, Sheroi; Kirking, Hannah L; Rolfes, Melissa A R; Olivo, Vanessa; Merrill, Lori; Battan-Wraith, Steph; Sano, Ellen; McLaren, Son H; Vargas, Celibell Y; Goodman, Sara; Sarnquist, Clea C; Govindaranjan, Prasanthi; Petrie, Joshua G; Belongia, Edward A; Ledezma, Karla; Pryor, Kathleen; Lutrick, Karen; Bullock, Ayla; Yang, Amy; Haehnel, Quenla; Rao, Suchitra; Zhu, Yuwei; Schmitz, Jonathan; Hart, Kimberly; Grijalva, Carlos G; Salvatore, Phillip P
Clinical infectious diseases, 2024-May-15, 2024-05-15, 20240515, Volume: 78, Issue: 5Journal Article
Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus disease 2019 (COVID-19); however, rebound after treatment has been reported. We compared symptom and viral dynamics in individuals with COVID-19 who completed N/R treatment and similar untreated individuals. We identified symptomatic participants who tested severe acute respiratory syndrome coronavirus 2-positive and were N/R eligible from a COVID-19 household transmission study. Index cases from ambulatory settings and their households contacts were enrolled. We collected daily symptoms, medication use, and respiratory specimens for quantitative polymerase chain reaction for 10 days during March 2022-May 2023. Participants who completed N/R treatment (treated) were propensity score matched to untreated participants. We compared symptom rebound, viral load (VL) rebound, average daily symptoms, and average daily VL by treatment status measured after N/R treatment completion or 7 days after symptom onset if untreated. Treated (n = 130) and untreated participants (n = 241) had similar baseline characteristics. After treatment completion, treated participants had greater occurrence of symptom rebound (32% vs 20%; P = .009) and VL rebound (27% vs 7%; P < .001). Average daily symptoms were lower among treated participants without symptom rebound (1.0 vs 1.6; P < .01) but not statistically lower with symptom rebound (3.0 vs 3.4; P = .5). Treated participants had lower average daily VLs without VL rebound (0.9 vs 2.6; P < .01) but not statistically lower with VL rebound (4.8 vs 5.1; P = .7). Individuals who completed N/R treatment experienced fewer symptoms and lower VL but rebound occured more often compared with untreated individuals. Providers should prescribe N/R, when indicated, and communicate rebound risk to patients.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.